Pharmaceutical pricing in Latin America demands balance. A price that is too high can close coverage doors, generate payer resistance, and limit access. A price that is too low can erode margin, affect prices in other markets, and make local investment harder.

The region combines public and private systems, high out-of-pocket spending pressure, a strong presence of generics, growing demand for innovation, and pricing policies that connect markets to one another. That combination turns pricing into a strategic decision, not an administrative calculation.

The Latin American pharmaceutical landscape

Market size estimates vary depending on the definition used, but they agree on sustained growth. Grand View Research estimated that the Latin American pharmaceutical market generated USD 78.3 billion in 2025 and projected a compound annual growth rate of 5.3 percent between 2026 and 2033 [1].

The financing context makes price sensitivity high. In Latin America and the Caribbean, 32.4 percent of total health spending was paid out of pocket in 2019 [2]. In Chile, an IDB study reported that 32 percent of total health spending was paid directly by households and that 40 percent of that spending corresponded to medicines [3].

The commercial consequence is clear: price affects coverage, real access, adherence, and value perception. It also affects regional negotiation, because many countries observe external prices when regulating or negotiating.

External reference pricing: markets connected by price

External reference pricing, or ERP, consists of using a medicine's prices in other countries as a reference to set or negotiate the local price. The practice is widespread. In 2019, 23 of 27 European Union countries used some form of ERP, and it was also applied in markets such as Australia, Brazil, Canada, Jordan, and South Africa [5].

The logic of ERP is to contain costs and prevent a country from paying more than comparable markets. Its strategic effect is more complex: it connects pricing decisions across countries. A low price in a referenced market can generate pressure to reduce prices elsewhere. That is why companies must think about price corridors, launch sequencing, and international exposure.

ERP can also generate unintended effects. Health Action International warns that lower-price countries may experience launch delays, and that extended use of ERP can push international strategies that reduce price transparency [6].

Differential pricing: attractive in theory, difficult in practice

Economic theory favors differential pricing for innovative medicines: higher prices in markets with greater ability to pay, lower prices in markets with less ability, and greater global access without destroying innovation incentives.

In practice, two forces limit that approach.

Arbitrage and political pressure: when there are large price differences between countries, the incentives for parallel imports, exceptional purchases, or public pressure to match low prices increase.
International reference pricing: if a low-price country appears in another's reference basket, the local discount can spread.

The result is usually a narrower price corridor than each market's ability to pay would suggest. Companies end up adjusting for negotiating power, regulatory risk, and expected volume, rather than for a simple formula based on per capita income.

Value-based pricing: justifying the price with clinical value

Value-based pricing seeks to align price with clinical and economic benefit. A technology with better survival, fewer hospitalizations, or higher quality of life can justify a higher price if the incremental value is well documented.

This approach requires evidence. Payers need cost-effectiveness models, budget impact, local resource utilization data, and clarity about uncertainty. In markets with more developed HTA agencies, such as Brazil, this evidence carries increasing weight in the conversation about adoption and price.

The problem arises when infrastructure is lacking. Without local data, the value argument becomes more fragile. That is why regional evidence generation is becoming a central component of pricing in Latin America.

Risk-sharing agreements and pay-for-performance

When there is uncertainty about a technology's real performance, managed entry agreements, risk-sharing contracts, and pay-for-performance schemes can help close the gap between expected price and observed value.

These agreements may include retrospective discounts, refunds for non-response, spending caps, price-volume agreements, or payments conditioned on clinical outcomes. The OECD documents that performance-based managed entry agreements have been used to manage uncertainty and improve coverage decisions for new medicines [8].

The difficulty is operational. Measuring outcomes, tracking patients, auditing compliance, and executing financial adjustments require robust information systems. In many Latin American markets, that infrastructure is still uneven. That is why simple financial agreements tend to be easier to implement than outcomes-based contracts.

Sequential launch strategy

Because ERP connects prices, many companies use sequential launch strategies. They seek to start in markets with greater flexibility or lower exposure to international reference, establish a favorable corridor, and then negotiate in stricter markets.

In Latin America, this can mean prioritizing private segments or markets with greater willingness to pay, while preparing local evidence for public negotiations. The strategy must manage reputational risk: delaying access in certain countries can generate political pressure, litigation, or deterioration of relationships with authorities.

Local data: the argument that sustains the price

Payers in the region increasingly demand local evidence. They want to know how many patients are eligible, what costs are avoided, what outcomes are relevant to their system, and what impact adoption will have on the budget.

The World Bank has shown that out-of-pocket pharmaceutical spending remains a relevant and heterogeneous burden in the region [4]. That reality raises the pressure to justify every price, especially when the medicine competes for public resources or for households' ability to pay.

Local evidence can include observational studies, patient registries, resource utilization analyses, budget impact models, and real-world evidence. It is not always cheap, but it can be decisive in defending a premium price before a sophisticated payer.

Technology tools to optimize pricing

In the past, developing a regional pricing strategy required extensive manual analyses: reviewing regulation country by country, mapping ERP baskets, simulating penetration scenarios, calculating budget impact, and estimating the consequences of price changes.

AI-driven platforms and advanced analytics can accelerate that work. They integrate regulatory databases, simulate ERP interdependencies, model price and access scenarios, and allow objectives to be compared: maximizing revenue, expanding access, reducing regulatory risk, or protecting the international corridor.

The final decision remains strategic. Technology does not eliminate negotiation, but it allows companies to reach it with more scenarios, better assumptions, and a clearer view of the risks.

Conclusion

Pharmaceutical pricing in Latin America goes far beyond marginal cost. It requires understanding financing, access, local evidence, ERP, political pressure, elasticity, implementation capacity, and the company's global objectives.

Pharmaceutical companies that master this complexity will be better able to defend their prices, expand access, and avoid decisions that generate unintended effects in other markets. In a region where each price point can define inclusion or exclusion from coverage, data-driven strategic pricing is a competitive capability.

At Quantus, we help market access, pricing, and HEOR teams build value, evidence, and price strategies for markets across the Americas. If you want to model regional pricing scenarios with greater traceability, write to us.

Sources

[1] Grand View Research. Latin America Pharmaceutical Market Size & Outlook, 2033. 2025. Available at: https://www.grandviewresearch.com/horizon/outlook/pharmaceutical-market/latin-america

[2] OECD/The World Bank. Health at a Glance: Latin America and the Caribbean 2023. OECD Publishing. 2023. Available at: https://www.oecd.org/en/publications/health-at-a-glance-latin-america-and-the-caribbean-2023_532b0e2d-en.html

[3] Atal, J. P., et al. ¿Cuánto podrían ahorrar y qué ganarían los hogares chilenos usando medicamentos genéricos en vez de sus equivalentes de marca? Banco Interamericano de Desarrollo. 2023. Available at: https://publications.iadb.org/en/cuanto-podrian-ahorrar-y-que-ganarian-los-hogares-chilenos-usando-medicamentos-genericos-en-vez-de

[4] Vargas, V., et al. Pharmaceuticals in Latin America and the Caribbean: Players, Access, and Innovation Across Diverse Models. World Bank. 2022. Available at: https://openknowledge.worldbank.org/entities/publication/e5fae256-f0c0-5400-9c14-b80387e182c8

[5] Commonwealth Fund. External Reference Pricing: The Drug-Pricing Reform America Needs? 2021. Available at: https://www.commonwealthfund.org/publications/issue-briefs/2021/may/external-reference-pricing-drug-pricing-reform-america-needs

[6] Health Action International. External Reference Pricing. Policy Brief. 2015. Available at: https://haiweb.org/wp-content/uploads/2015/07/Policy-Brief-1-External-Reference-Pricing.pdf

[7] OECD. Pharmaceutical Pricing Policies in a Global Market. OECD Publishing. 2008. Available at: https://www.oecd.org/en/publications/pharmaceutical-pricing-policies-in-a-global-market_9789264044159-en.html

[8] Wenzl, M., & Chapman, S. Performance-based managed entry agreements for new medicines in OECD countries and EU member states. OECD Health Working Papers No. 115. 2019. Available at: https://www.oecd.org/en/publications/performance-based-managed-entry-agreements-for-new-medicines-in-oecd-countries-and-eu-member-states_6e5e4c0f-en.html